

BC CANCER HAZARDOUS DRUG LIST

(Refer to: Pharmacy Directive VI-80 Hazardous Drug List)

The BC Cancer Hazardous Drug List (BC Cancer HD List) is comprised of:

- drugs listed as hazardous in the currently published *National Institute for Occupational Safety and Health-US (NIOSH) List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings* (i.e., NIOSH List)

AND

- drugs evaluated as hazardous by BC Cancer (refer to BC Cancer Provincial Pharmacy Directive VI-80 *Hazardous Drug List* for details regarding the evaluation process).

The drugs reviewed for the following list include only those drugs approved for use at BC Cancer regional centres as per the [BC Cancer Benefit Drug List](#) or via the BC Cancer Compassionate Access Program (CAP). For non-oncology drugs, refer to the complete NIOSH 2016 List <http://www.cdc.gov/niosh/docs/2016-161/>

The BC Cancer HD List will be posted in each BC Cancer Regional Cancer Centre Pharmacy. For guidelines on the safe handling of hazardous drugs at BC Cancer, refer to BC Cancer Provincial Pharmacy Directive VI-40 *Safe Handling and Preparation of Hazardous Drug Dosage Forms*.

An asterisk (*) after the drug name on the BC Cancer HD List will signify drugs which have been designated as *biohazardous* (BioHD) at BC Cancer.

BCCA HD List

abiraterone ¹	enzalutamide ¹	PACLitaxel ¹
acitretin ³	epirubicin ¹	PACLitaxel, nab ⁴
AFAtinib ¹	eriBULin ¹	palbociclib ⁴
alectinib ⁴	erlotinib ¹	pamidronate ³
amsacrine ¹	estramustine ¹	PAZOPanib ¹
anastrozole ¹	etoposide ¹	pemetrexed ¹
arsenic trioxide ¹	everolimus ¹	PERTuzumab ¹
atezolizumab ⁴	exemestane ¹	plerixafor ³
avelumab ⁴		pomalidomide ¹
aXitinib ¹		PONATtinib ¹
azaCITIDine ¹	fludarabine ¹	procarbazine ¹
	fluorouracil ¹	
Bacillus Calmette - Guerin (BCG) ^{*1}	flutamide ¹	
belinostat ¹	fulvestrant ¹	
bendamustine HCl ¹		quinagolide ⁴
bexarotene ¹	gemcitabine ¹	
bicalutamide ¹	goserelin ¹	
bleomycin ¹		raltitrexed ⁴
blinatumomab ⁴		regorafenib ¹
bortezomib ¹	hydroxyUREA ¹	romiDEPsin ¹
bosutinib ¹		ruxolitinib ⁴
brentuximab vedotin ¹	IDArubicin ¹	
buserelin ⁴	ifosfamide ¹	
busulfan ¹	iMAtinib mesylate ¹	SORAFenib ¹
	irinotecan HCl ¹	streptozocin ¹
cabazitaxel ¹	irinotecan, liposome ⁴	SUNItinib malate ¹
cabergoline ³	ixabepilone ¹	
capecitabine ¹		
CARBOplatin ¹	lanreotide ⁴	tamoxifen ¹
carfilzomib ¹	lapatinib ⁴	temozolomide ¹
carmustine ¹	lenalidomide ²	temsirolimus ¹
ceritinib ⁴	lenvatinib ⁴	teniposide ¹
chlorambucil ¹	letrozole ¹	testosterone ³
CISplatin ¹	leuprolide acetate ¹	thalidomide ²
cladribine ¹	lomustine ¹	thioguanine ¹
cobimetinib ⁴		thiotepa ¹
crizotinib ¹		topotecan ¹
cyclophosphamide ¹	mechlorethamine ¹	trametinib ¹
cycloSPORINE ²	medroxyPROGESTERone acetate ²	trastuzumab (HERCEPTIN®) ⁴
cytarabine ¹	megestrol ¹	trastuzumab emtansine (KADCYLA®) ¹
	melphalan ¹	TRC105 (carotuximab) ⁴
daBRAFeNib ¹	mercaptapurine ¹	tretinoin ³
dacarbazine ¹	methotrexate ¹	
DACTINomycin ¹	mitomycin ¹	
daratumumab ⁴	mitotane ¹	
daSATinib ¹	mitoXANTRONE ¹	vanDETanib ¹
DAUNOrubicin HCl ¹		vemURAFenib ¹
degarelix ¹		vinBLAStine sulfate ¹
dexrazoxane ²	niLOtinib ¹	vinCRIStine sulfate ¹
DOCEtaxel ¹		vinorelbine tartrate ¹
DOXOrubicin ¹	olaparib ⁴	vismodegib ¹
DOXOrubicin, pegylated liposomal ⁴	olaratumab ⁴	
durvalumab ⁴	osimertinib ⁴	
	oxaliplatin ¹	zoledronic acid ³

* designated as *biohazardous* (BioHD) at BC Cancer.

Numerical superscripts **1, 2, or 3** refer to tables contained within the NIOSH 2014 List as below:

1. NIOSH Table 1 (hazardous antineoplastic drugs)
2. NIOSH Table 2 (hazardous non-antineoplastic drugs)
3. NIOSH Table 3 (hazardous non-antineoplastic drugs with primarily reproductive effects)

Numerical superscript **4** refers to drugs evaluated by BC Cancer per Provincial Pharmacy Directive VI-80 *Hazardous Drug List*.

NOTES: For guidelines on the safe handling of hazardous drugs at BC Cancer, refer to BC Cancer Provincial Pharmacy Directive VI-40 *Safe Handling and Preparation of Hazardous Drug Dosage Forms*. For the complete NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings (2014), refer to <http://www.cdc.gov/niosh/docs/2014-138>